Sonnet BioTherapeutics Holdings, Inc. Made Big Gain

Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) soared at $1.93, a gain of 66.4%. On Mon, Oct 31, 2022, SONN:NASDAQ touched a New 2-Week High of $1.93. The stock got featured on our News Catalysts scanner on Mon, Oct 31, 2022 at 08:27 AM in the 'AGREEMENT' category. From Mon, Oct 17, 2022, the stock recorded 30.00% Up Days and 45.45% Green Days
The stock spiked on Mon, Oct 31, 2022 at $2.68 with a volume of 101M+.
About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)
Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.
Top 10 Gainers:
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 66.38%
- Acorda Therapeutics, Inc. (ACOR:NASDAQ), 63.36%
- Bull Horn Holdings Corp. (BHSE:NASDAQ), 44.67%
- Actinium Pharmaceuticals, Inc. (ATNM:NYSEMKT), 39.16%
- Shineco Inc. (SISI:NASDAQ), 37.96%
- Getty Images Holdings Inc. Class A (GETY:NYSE), 34.65%
- Sientra, Inc. (SIEN:NASDAQ), 31.11%
- Renovare Environmental Inc. (RENO:NASDAQ), 28.57%
- Aravive, Inc. (ARAV:NASDAQ), 23.58%
- Mondee Holdings Inc. (MOND:NASDAQ), 22.46%